Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) and keeping the price target at $102.00.
Joseph Pantginis has given his Buy rating due to a combination of factors including the promising progress of Viking Therapeutics’ VK2735 drug. The completion of enrollment for the Phase 2 VENTURE-Oral trial marks a significant milestone, with data expected in the second half of 2025. This trial aims to evaluate the safety and efficacy of VK2735 in weight loss, and the drug has shown strong results in previous clinical readouts, suggesting it could stand out in the competitive weight loss market.
Moreover, Viking’s recent manufacturing agreement with CordenPharma ensures a robust supply chain for both the oral and subcutaneous formulations of VK2735. This strategic move positions Viking well for potential commercialization, as it secures large-scale production capacity in anticipation of growing demand in the obesity treatment market. Additionally, Viking’s retention of full global rights to VK2735 allows for complete control over its development, further supporting the Buy rating with a price target of $102.
Pantginis covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Cytokinetics, and Esperion. According to TipRanks, Pantginis has an average return of -11.8% and a 27.25% success rate on recommended stocks.